Expression of plasma microRNA-145-5p and its correlation with clinical features in patients with refractory epilepsy.
The potential of microRNAs (miRNAs) as biomarkers has been explored in various brain diseases, including epilepsy. In this study, we are aiming to analyze the aberrant expression of miRNA-145-5p in patients with refractory epilepsy, and to further explore the correlation with clinical features. The study cohort comprised 40 patients with refractory epilepsy and 42 healthy controls. MiRNA-145-5p expression levels in plasma were analyzed by quantitative real-time polymerase chain reaction (qRT-PCR). Data analysis was performed using IBM SPSS Statistics 22.0. Compared with healthy controls, the expression of miRNA-145-5p in plasma was downregulated significantly in the patients with refractory epilepsy (1.180 ± 1.036 vs. 1.541 ± 0.936, p = 0.033) and mesial temporal lobe epilepsy (MTLE) (0.517 ± 0.483 vs. 1.541 ± 0.936, p = 0.004). ROC analysis showed that the area under the curve (AUC) was 0.632 (95%CI: 0.508-0.755; P = 0.040) in refractory epilepsy and 0.829 (95%CI: 0.702-0.955; P = 0.001) in MTLE. Furthermore, the expression of miRNA-145-5p was positively correlated with earlier age at epilepsy onset, more frequent seizures and past history. We suggested that decreased expression of miRNA-145-5p could be a potential non-invasive biomarker for early detection and clinical evaluation of refractory epilepsy. However, further studies are still required.